Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07431866 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT07431866 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 41 participants.
The verdict
NCT07431866, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
Researchers are looking for other ways to treat people who have heart failure with preserved ejection fraction (HFpEF). HFpEF is a type of heart failure where the heart becomes stiff and does not relax properly. MK-2828 is a study medicine designed to treat HFpEF. The main goal of the study is to learn if MK-2828 affects what happens to rosuvastatin or furosemide in the body.
Interventions
- DRUG Furosemide
- DRUG MK-2828
- DRUG Rosuvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2026-03-18 |
| Est. Completion | 2026-06-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07431866
The ClinicalTrials.gov registry entry for NCT07431866 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Furosemide is the first listed.
NCT07431866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07431866 about?
NCT07431866 is a clinical study titled "A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)". Researchers are looking for other ways to treat people who have heart failure with preserved ejection fraction (HFpEF). HFpEF is a type of heart failure where the heart becomes stiff and does not relax properly. MK-2828 is a study medicine designed to treat HFpEF. The main goal of the study is to l...
What is the current status of trial NCT07431866?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2026-03-18. Estimated completion is 2026-06-13.
What interventions are being tested in trial NCT07431866?
The interventions under investigation include: Furosemide (DRUG), MK-2828 (DRUG), Rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT07431866?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.